Invention Grant
- Patent Title: Anti-CXCL13 antibodies
-
Application No.: US16963130Application Date: 2019-09-18
-
Publication No.: US11028164B2Publication Date: 2021-06-08
- Inventor: Haijuan Gu , Qiumei Yang
- Applicant: I-Mab Biopharma US Limited
- Applicant Address: US MD Gaithersburg
- Assignee: I-Mab Biopharma US Limited
- Current Assignee: I-Mab Biopharma US Limited
- Current Assignee Address: US MD Gaithersburg
- Agency: Sheppard Mullin Richter & Hampton LLP
- Priority: WOPCT/CN2018/106158 20180918
- International Application: PCT/CN2019/106409 WO 20190918
- International Announcement: WO2020/057540 WO 20200326
- Main IPC: C07K16/24
- IPC: C07K16/24 ; A61P37/02 ; C07K16/28 ; A61K39/00 ; A61P35/00 ; G01N33/68
Abstract:
Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
Information query
